恶性疟治疗后间日疟原虫血症风险:世界抗疟药物耐药性网络个体患者数据荟萃分析
本研究基于42项研究、15341例患者的个体数据,量化了恶性疟经青蒿素联合疗法(ACT)治疗后42天和63天发生间日疟原虫血症的累积风险,并分析相关决定因素。结果显示不同ACT方案及地区复发周期性下风险差异显著,提示在特定人群中联合使用杀灭休眠子药物可能获益。
要点
- 恶性疟ACT治疗后间日疟原虫血症42天累积风险以甲氟喹-青蒿素最低(4.5%),蒿甲醚-苯芴醇最高(31.1%)。
- 至63天累积风险进一步升高,双氢青蒿素-哌喹为12.8%,蒿甲醚-苯芴醇达39.9%。
- 短复发周期地区及未在2天内清除原虫者间日疟原虫血症风险显著增高。
核心结论
- 恶性疟治疗后间日疟原虫血症风险较高,且在不同研究和地区间差异显著。
- 这些间日疟感染可能源于复发,可通过包含杀灭休眠子药物的根治方案预防。
- 该策略的获益在不同地理区域差异很大。
研究设计与样本
- 系统检索Medline、Embase、Web of Science和Cochrane系统评价数据库,纳入1960年1月1日至2018年1月5日间在间日疟和恶性疟共流行区开展的ACT治疗无并发症恶性疟的疗效研究。
- 共纳入42项研究、15341例患者,包括30项随机对照试验和12项队列研究。
- 采用多变量Cox回归分析42天和63天间日疟原虫血症风险及相关因素,研究质量采用Joanna Briggs Institute工具评估,并在PROSPERO注册(CRD42018097400)。
主要发现
- 42天累积风险:蒿甲醚-苯芴醇31.1%(95%CI 28.9-33.4),青蒿琥酯-阿莫地喹14.1%(95%CI 10.8-18.3),青蒿琥酯-甲氟喹7.4%(95%CI 6.7-8.1),双氢青蒿素-哌喹4.5%(95%CI 3.9-5.3)。
- 63天累积风险:蒿甲醚-苯芴醇39.9%(95%CI 36.6-43.3),青蒿琥酯-阿莫地喹42.4%(95%CI 34.7-51.2),青蒿琥酯-甲氟喹22.8%(95%CI 21.2-24.4),双氢青蒿素-哌喹12.8%(95%CI 11.4-14.5)。
- 多变量分析中,短复发周期地区患者42天内间日疟原虫血症风险最高(AHR=6.2,95%CI 2.0-19.5;p=0.002);与双氢青蒿素-哌喹相比,蒿甲醚-苯芴醇(AHR=6.2,95%CI 4.6-8.5;p<0.001)、青蒿琥酯-阿莫地喹(AHR=2.3,95%CI 1.4-3.7;p=0.001)和青蒿琥酯-甲氟喹(AHR=1.4,95%CI 1.0-1.9;p=0.028)风险更高;未在2天内清除原虫者风险增高(AHR=1.8,95%CI 1.4-2.3;p<0.001)。
临床怎么用
- 在间日疟和恶性疟共流行区,选择ACT方案时应考虑间日疟原虫血症风险,双氢青蒿素-哌喹风险较低。
- 对短复发周期地区或原虫清除延迟的患者,可评估联合杀灭休眠子药物进行根治的必要性。
- 根治策略的获益因地理区域而异,需结合当地复发周期性制定政策。
局限性
- 研究人群间存在异质性。
- 缺乏极低传播地区的数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is a high risk of Plasmodium vivax parasitaemia following treatment of falciparum malaria. Our study aimed to quantify this risk and the associated determinants using an individual patient data meta-analysis in order to identify populations in which a policy of universal radical cure, combining artemisinin-based combination therapy (ACT) with a hypnozoitocidal antimalarial drug, would be beneficial. METHODS AND FINDINGS: A systematic review of Medline, Embase, Web of Science, and the Cochrane Database of Systematic Reviews identified efficacy studies of uncomplicated falciparum malaria treated with ACT that were undertaken in regions coendemic for P. vivax between 1 January 1960 and 5 January 2018. Data from eligible studies were pooled using standardised methodology. The risk of P. vivax parasitaemia at days 42 and 63 and associated risk factors were investigated by multivariable Cox regression analyses. Study quality was assessed using a tool developed by the Joanna Briggs Institute. The study was registered in the International Prospective Register of Systematic Reviews (PROSPERO: CRD42018097400). In total, 42 studies enrolling 15,341 patients were included in the analysis, including 30 randomised controlled trials and 12 cohort studies. Overall, 14,146 (92.2%) patients had P. falciparum monoinfection and 1,195 (7.8%) mixed infection with P. falciparum and P. vivax. The median age was 17.0 years (interquartile range [IQR] = 9.0-29.0 years; range = 0-80 years), with 1,584 (10.3%) patients younger than 5 years. 2,711 (17.7%) patients were treated with artemether-lumefantrine (AL, 13 studies), 651 (4.2%) with artesunate-amodiaquine (AA, 6 studies), 7,340 (47.8%) with artesunate-mefloquine (AM, 25 studies), and 4,639 (30.2%) with dihydroartemisinin-piperaquine (DP, 16 studies). 14,537 patients (94.8%) were enrolled from the Asia-Pacific region, 684 (4.5%) from the Americas, and 120 (0.8%) from Africa. At day 42, the cumulative risk of vivax parasitaemia following treatment of P. falciparum was 31.1% (95% CI 28.9-33.4) after AL, 14.1% (95% CI 10.8-18.3) after AA, 7.4% (95% CI 6.7-8.1) after AM, and 4.5% (95% CI 3.9-5.3) after DP. By day 63, the risks had risen to 39.9% (95% CI 36.6-43.3), 42.4% (95% CI 34.7-51.2), 22.8% (95% CI 21.2-24.4), and 12.8% (95% CI 11.4-14.5), respectively. In multivariable analyses, the highest rate of P. vivax parasitaemia over 42 days of follow-up was in patients residing in areas of short relapse periodicity (adjusted hazard ratio [AHR] = 6.2, 95% CI 2.0-19.5; p = 0.002); patients treated with AL (AHR = 6.2, 95% CI 4.6-8.5; p < 0.001), AA (AHR = 2.3, 95% CI 1.4-3.7; p = 0.001), or AM (AHR = 1.4, 95% CI 1.0-1.9; p = 0.028) compared with DP; and patients who did not clear their initial parasitaemia within 2 days (AHR = 1.8, 95% CI 1.4-2.3; p < 0.001). The analysis was limited by heterogeneity between study populations and lack of data from very low transmission settings. Study quality was high. CONCLUSIONS: In this meta-analysis, we found a high risk of P. vivax parasitaemia after treatment of P. falciparum malaria that varied significantly between studies. These P. vivax infections are likely attributable to relapses that could be prevented with radical cure including a hypnozoitocidal agent; however, the benefits of such a novel strategy will vary considerably between geographical areas.
引用
- Hossain MS, Commons RJ, Douglas NM, et al. The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network. PLoS Med. 2020. PMID: 33211712. doi:10.1371/journal.pmed.1003393
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。